Astera Labs Inc

Stage 4 declining structure and the active Bearish Pivot Point confirm a medium-term sell bias. Price remains below the declining EMAs after an oversold bounce, suggesting further downside potential but lacking a clear timing edge for immediate execution. We will trim into resistance at the 9/20/50 EMA cluster. The long-term uptrend above the 200-day moving average persists but does not alter the current bearish medium-term stance.

• ↑Q2 revenue hit $392.4M, up 27% sequentially and 104% YoY
• ↑Scorpio product line set to dominate by Q3, boosting sales mix
• ↓Valuation stretched at ~137x forward earnings versus peers